Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.

Trial Profile

Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Ethinylestradiol/levonorgestrel (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Acronyms NEW CHOICE
  • Sponsors Agile Therapeutics
  • Most Recent Events

    • 22 Dec 2017 According to an Agile Therapeutics media release, the CRL identifies deficiencies relating to quality adhesion test methods and also noted that observations identified during an inspection of a facility of the Company's third-party manufacturer, Corium International Inc., (Corium), for the Twirla NDA must be resolved. The CRL also questions the in vivo adhesion properties of Twirla and their potential relationship to the SECURE phase 3 clinical trial results.
    • 22 Dec 2017 According to an Agile Therapeutics media release, the U.S. Food and Drug Administration issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for Twirla (AG200-15). The CRL states that the FDA has determined that it cannot approve the NDA in its present form. The CRL recommends that the Company address the implications of clinical trial subject patch compliance and the withdrawal and dropout rates and does not identify any specific safety issues.
    • 22 Dec 2017 According to an Agile Therapeutics media release, the Company has submitted an amendment to the NDA in response to an information request from the FDA on the issues related to quality adhesion test methods cited in the CRL. The facility also provided the FDA responses addressing each of the observations made during the FDA's facility inspection. The CRL acknowledges receipt of the Company's NDA amendment and states that the amendment was not reviewed prior to the FDA's action.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top